Adult paroxysmal cold hemoglobinuria following mRNA COVID‐19 vaccination

Abstract

Paroxysmal cold hemoglobinuria (PCH) is an extremely rare subtype of autoimmune hemolytic anemia (AIHA) in adults. PCH is caused by the biphasic Donath–Landsteiner (DL) antibody which fixes complement to red blood cells at low temperatures and dissociates at warmer temperatures, leading to complement‐mediated intravascular hemolysis. Autoimmune hematological disorders including AIHA and immune thrombocytopenia have been reported to develop following the mRNA COVID‐19 vaccination. However, PCH developing subsequent to mRNA vaccination has never been reported. We report a 59‐year‐old male who developed PCH approximately a month after his second mRNA COVID‐19 vaccination.

Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4‐34 mutations after COVID‐19

“…Cold agglutinin syndrome (CAS) is associated with various LPDs. [1][2][3] CAD is categorized as an independent disease according to the fifth edition of the World Health Organization (WHO) classification of haematolymphoid tumours 1 and the International Consensus Classification (ICC) of mature lymphoid neoplasms. 4 Recurrent somatic mutations in KMT2D and CARD11 have been detected in CAD, whereas mutations in MYD88 L265P and CXCR4 and very rarely KMT2D mutations are detected in patients with lymphoplasmacytic lymphoma (LPL).…”